Display screen with a graphical user interface

- Nurocor, Inc.
Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description

The FIGURE is a front view of a display screen with a graphical user interface.

Claims

The ornamental design for a display screen with a graphical user interface, as shown and described.

Referenced Cited
U.S. Patent Documents
D344102 February 8, 1994 Polak
D502184 February 22, 2005 Glezer
7030890 April 18, 2006 Jouet
D594911 June 23, 2009 Hall
7818689 October 19, 2010 Wada
8286072 October 9, 2012 Chamberlain
D673577 January 1, 2013 Cojuangco
D698361 January 28, 2014 Stiffler
D715834 October 21, 2014 Siddons
D723048 February 24, 2015 Helliker
D732058 June 16, 2015 Landis
D753174 April 5, 2016 Cojuangco
D759072 June 14, 2016 Siddons
D769315 October 18, 2016 Scotti
D771107 November 8, 2016 Spector
D772276 November 22, 2016 Yampolskiy
D788790 June 6, 2017 Omata
D792448 July 18, 2017 Take
D799499 October 10, 2017 Selden
D803248 November 21, 2017 Sunshine
D819687 June 5, 2018 Yampolskiy
D841030 February 19, 2019 Bradley-Pollack
D841031 February 19, 2019 Orlando
D841675 February 26, 2019 Hoffman
D854558 July 23, 2019 Melillo
D855634 August 6, 2019 Kim
D870762 December 24, 2019 Mendoza Corominas
D873846 January 28, 2020 Melillo
D877747 March 10, 2020 Belliveau
D880517 April 7, 2020 Imamura
D881927 April 21, 2020 Tsukahara
D882598 April 28, 2020 Belliveau
10613711 April 7, 2020 Makovsky
D895642 September 8, 2020 Hoofnagle
D900840 November 3, 2020 Dudey
D916869 April 20, 2021 Evangeliou
D922422 June 15, 2021 Molander
D924906 July 13, 2021 Nie
D924909 July 13, 2021 Nasu
D928194 August 17, 2021 Baker
11132552 September 28, 2021 Naslavsky
D937862 December 7, 2021 Anderson
D950580 May 3, 2022 Ahmed
D963677 September 13, 2022 Bahatyrevich
D978887 February 21, 2023 Caro
D980863 March 14, 2023 Balsamo
D985602 May 9, 2023 Walecka
D1040175 August 27, 2024 Potash
D1052603 November 26, 2024 Ganapathy
D1055947 December 31, 2024 Harmon
D1060404 February 4, 2025 Arora
D1061592 February 11, 2025 Khokhar
20050055241 March 10, 2005 Horstmann
20080120574 May 22, 2008 Heredia
20110153358 June 23, 2011 Campo et al.
20130232104 September 5, 2013 Goyal et al.
20140039921 February 6, 2014 Broverman et al.
20150213547 July 30, 2015 Gomez-Rosado
20170075557 March 16, 2017 Noble
20170147794 May 25, 2017 Harder
20170286456 October 5, 2017 Wenzel et al.
20170323320 November 9, 2017 Mendoza Corominas
20180039399 February 8, 2018 Kaltegaertner et al.
20180261305 September 13, 2018 Lindblad
20200335188 October 22, 2020 Ozeran
20200394612 December 17, 2020 Khokhar
20220004540 January 6, 2022 Watson et al.
20220005554 January 6, 2022 Malfait et al.
20220005555 January 6, 2022 Malfait et al.
20220005558 January 6, 2022 Malfait et al.
20230274809 August 31, 2023 Dimitrova
20230360779 November 9, 2023 Gnanasambandam et al.
Other references
  • Kemegne, Gislaine Aurelie et al., Comparing checkerboard, isobologram and CCD methods for drug combination, Oct. 31, 2021, AcademicJournals.org, retrieved Oct. 24, 2023, https://academicjournals.org/journal/JMPR/article-full-text/C8764D068023 (Year: 2021).
  • Dandapandi, Hari G., Leveraging Mobile-Based Sensors for Clinical Research, Jun. 13, 2022, FrontiersIn.org, retrieved Feb. 28, 2025, https://www.frontiersin.org/journals/digital-health/articles/10.3389/fdgth.2022.893070/full (Year: 2022).
  • Kriebel, Andy, How to Create a Dot Strip Plot, Jun. 8, 2021, YouTube.com, retrieved Feb. 28, 2025, https://www.youtube.com/watch?v=fKSL-IMqILA (Year: 2021).
  • “Clinical trials and their patients: The rising costs and how to stem the loss,” Pharmafile, accessed from http:/www.pharmafile.com/print/511225, Mar. 11, 2016, 6 pp.
  • “ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials,” European Medicines Agency, Committee for Medicinal Products for Human Use, EMA/CHMP/CH/4362221/2017, Feb. 17, 2020, 19 pp.
  • “Nurocor Clinical Platform—Technical Perspective,” Nurocor, Inc., accessed on Apr. 29, 2020, 11 pp.
  • “Optimize Clinical Development,” Nurocor and Intilaris brochure, accessed on Sep. 9, 2020, 2 pp.
  • Nelson et al., “CDISC 2019 US Interchange,” [Presentation], CDISC, San Diego, CA, Oct. 14-18, 2019, 19 pp.
  • Kountouris et al., “Efficient scheduling of conditional behaviors for high-level synthesis,” ACM Transactions on Design Automation of Electronic Systems, vol. 7, No. 3, Jul. 1, 2002, pp. 380-412.
  • Lin et al., “A Standard-Driven Approach for Electric Submission to Pharmaceutical Regulatory Authorities”, Journal of Biomedical Informatics, vol. 79, Jan. 31, 2018, pp. 60-70.
  • “Executive Summary—Digital Data Flow Solution Framework and Conceptual Design, Version 1.0,” TransCelebrate Biopharma, Inc., Nov. 7, 2019, 4 pp.
  • “Digital Data Flow Solution Framework and Conceptual Design, Version 1.0,” TransCelebrate DDF Project Team, TransCelebrate Biopharma, Inc., Nov. 1, 2019, 46 pp.
  • “Reusable Asset Specification, Version 2.2,” Object Management Group (OMG), accessed from https://www.omg.org/spec/RAS/2.2/PDF, Nov. 2005, 121 pp.
  • Nelson et al., PowerPoint presented at 2019 Clinical Data Interchange Standards Consortium (CDISC) US Interchange, San Diego, California, Oct. 14-18, 2018, 19 pp.
  • “Cost of Developing a New Drug,” Tufts Center for the Study of Drug Development (CSDD), Tufts University, School of Medicine, Nov. 18, 2014, 30 pp.
  • “Drug Approval Process—Infographic,” U.S. Food and Drug Administration (FDA), accessed from http://www.fda.gov/downloads/Drugs/ResourcesForYou/Consumers/UCM284393.pdf, accessed on Jan. 20, 2015, 2 pp.
  • Burrows, “Report: The 8 biggest challenges facing clinical trail professionals,” Informa Connect, Clinical & Medical Affairs, accessed from https://informaconnect.com/report-biggest-challenges-clinical-trials-pt-1/, Nov. 30, 2016, 4 pp.
  • Nelson et al., “3D Standardized in Clinical Development to achieve End-to-End Automation,” Intilaris, Nurocor, 2019 Clinical Data Interchange Standards Consortium (CDISC), Oct. 14-18, 2019, 5 pp.
  • “How to avoid costly clinical research delays,” MESM Blog, accessed from https://www.mesm.com/blog/tips-to-help-you-avoid-costly-clinical-research-delays/, dated Jan. 16, 2020, accessed on Mar. 4, 2021, 4 pp.
  • Hargreaves, “Clinical trails and their patients: The rising costs and how to stem the loss,” Pharmafile, accessed from http://www.pharmafile.com/news/511225/clinical-trials-and-their-patients-rising-costs-and-how-stem-loss, Mar. 11, 2016, 8 pp.
  • Woodcock et al., “Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both,” Massachusetts Medical Society, The New England Journal of Medicine, Jul. 6, 2017, 9 pp.
  • “Nurocor products allow customers to automate clinical development processes from protocol to submission,” NUROCOR Brochure, accessed from www.nurocor.com, accessed on Sep. 10, 2019, 4 pp.
  • “Streamline Your Clinical Operations Through Smarter Standardization,” Nurocor, PowerPoint presented at 2019 Clinical Data Interchange Standards Consortium (CDISC), US Interchange, San Diego, California, Oct. 18, 2019, 22 pp.
  • “Facts about Clinical Trials,” Arena International, accessed from https://web.archive.org/web/20180914235739/http://www.arena-international.com/clinicaltrials/facts-about-clinical-trials/1063.article, dated Sep. 14, 2018, accessed on Mar. 4, 2021, 1 pp.
  • “Study Data Tabulation Model Implementation Guide: Human Clinical Trials,” Prepared by the CDISC Submission Standards Team, cdisc, Version 3.3 (Final), Clinical Data Interchange Standards Consortium, Inc., Nov. 20, 2018, 426 pp.
  • “Biotech Out-Licensed Optimized Compound Value—Product Oriented Licensing Strategy,” Intilaris LifeSciences, accessed on Sep. 9, 2020, 6 pp.
  • Ganic et al., “PhUSE EU Connect 2018—Structure and Standardized Study Definition drives early study setup for added business benefits,” Bayer, Intilaris, Nov. 2018, 20 pp.
  • Getz et al., “Measuring the Incidence, Causes, and Repercussions of Protocol Amendments,” Therapeutic Innovation and Regulatory Science, Drug Information Journal, vol. 45, Issue 3, May 2011, pp. 265-275.
  • Seguine, “Overcoming the Industry's Data Crisis,” Clinical Link, EPC, Aug. 2019, pp. 38-41.
  • “The Case for CDISC Standards,” CDISC, Business Case for CDISC Standards, Stage V, Sep. 30, 2014, 45 pp.
  • “Information technology—Metadata registries (MDR)—Part 1: Framework,” International Standards, ISO/IEC 11179-1, Second Edition, Sep. 15, 2004, 32 pp.
  • “Information technology—Metadata registries (MDR)—Part 2: Classification,” International Standards, ISO/IEC 11179-2, Second Edition, Nov. 15, 2005, 16 pp.
  • “Information technology—Metadata registries (MDR)—Part 3: Registry metamodel and basic attributes,” International Standards, ISO/IEC 11179-3, Third Edition, Feb. 15, 2013, 244 pp.
  • “Information technology—Metadata registries (MDR)—Part 4: Formulation of data definitions,” International Standards, ISO/IEC 11179-4, Second Edition, Jul. 15, 2004, 16 pp.
  • “Information technology—Metadata registries (MDR)—Part 5: Naming principles,” International Standards, ISO/IEC 11179-5, Third Edition, Apr. 1, 2015, 32 pp.
  • “Information technology—Metadata registries (MDR)—Part 6: Registration,” International Standards, ISO/IEC 11179-6, Third Edition, Aug. 1, 2015, 72 pp.
  • Advisory Action from U.S. Appl. No. 17/305,366 dated Jan. 3, 2025, 2 pp.
  • Response to Final Office Action dated Sep. 18, 2024 from U.S. Appl. No. 17/305,368 filed Dec. 17, 2024, 17 pp.
  • Response to Final Office Action dated Sep. 28, 2024 from U.S. Appl. No. 17/305,366 filed Nov. 27, 2024, 18 pp.
  • Jiang et al., “Using Semantic Web technologies for the generation of domain-specific templates to support clinical study metadata standards”, Journal of Biomedical Semantics, vol. 7, No. 10, BioMed Central, Mar. 6, 2016, 10 pp., https://doi.org/10.1186/s13326-016-0053-5.
  • Office Action from U.S. Appl. No. 17/305,366 dated Jan. 29, 2024, 32 pp.
  • Response to Office Action dated Jan. 29, 2024 from U.S. Appl. No. 17/305,366 filed May 29, 2024, 21 pp.
  • Response to Office Action dated Mar. 8, 2024 from U.S. Appl. No. 17/305,368 filed Jul. 8, 2024, 18 pp.
  • Office Action from U.S. Appl. No. 17/305,366 dated Mar. 24, 2025, 28 pp.
  • Final Office Action from U.S. Appl. No. 17/305,368 dated Apr. 22, 2025, 16 pp.
  • Response to Office Action dated Jan. 6, 2025 from U.S. Appl. No. 17/305,368 filed Apr. 7, 2025, 16 pp.
Patent History
Patent number: D1081702
Type: Grant
Filed: Nov 2, 2020
Date of Patent: Jul 1, 2025
Assignee: Nurocor, Inc. (Austin, TX)
Inventors: Frederik Malfait (Wolfenschiessen), Maurice Williams (Canton, MI), Robert Ross (Lumberton, NJ)
Primary Examiner: Katherine A Holbrow
Assistant Examiner: Christopher M Spivey
Application Number: 29/652,731
Classifications